More than 30 companies to start making Pfizer’s COVID pill

Nearly three dozen companies worldwide will soon start making generic versions of Pfizer’s coronavirus pill, the U.N.-backed Medicines Patent Pool that negotiated the deal said Thursday.

The Medicines Patent Pool said in a statement that agreements signed with 35 companies should help make Pfizer’s antiviral nirmatrelvir, or Paxlovoid, available to more than half of the world’s population.

Generic drugmakers across a dozen countries in Asia, the Caribbean, the Middle East and Eastern Europe will begin producing either the raw ingredients for the Pfizer drug or the pill itself. Among the companies offered a license was one in Ukraine, which has not yet been able to confirm it can participate.

“This will make an enormous difference for countries.” said Charles Gore, executive director of the Medicines Patent Pool. He said the availability of the Pfizer drug in some of the world’s poorest countries is especially critical. “They have been at the back of the queue for vaccines, so having a treatment like this in the armory will be absolutely critical to prevent deaths.”